OS Animal Health Highlights at Moody Capital Conference Amid Push for Canine Osteosarcoma Immunotherapy

OS Animal Health, a wholly owned subsidiary of OS Therapies Inc. (NYSE American: OSTX), has been featured in coverage of the Disruptive Growth & Life Sciences Conference, organized by Moody Capital Solutions. The company, dedicated to improving outcomes for pets with cancer, is focusing on developing and commercializing OST-HER2 for canine osteosarcoma and is working to re-establish USDA conditional approval to bring innovative immunotherapies to the veterinary oncology market.

The attention from the conference comes at a pivotal time for OS Animal Health. Osteosarcoma is the most common primary bone cancer in dogs, and current treatment options are limited and often ineffective. The company's OST-HER2 is being positioned as the “go-to” option for all HER2 positive cancers in dogs, and eventually for all companion animals. This positioning could establish a new standard of care in veterinary medicine, addressing a significant unmet medical need.

By participating in the Moody Capital Solutions 2026 Disruptive Growth and Life Sciences Conference, OS Animal Health aims to attract investors and partners to support its regulatory and commercialization efforts. The conference, which provides a platform for emerging growth companies to present their innovations, is an opportunity for OS Animal Health to showcase the potential of OST-HER2 to a broader financial and life sciences audience. The company's presence highlights the growing interest in veterinary oncology, a niche yet rapidly expanding sector within the broader animal health industry.

The implications of this announcement are multifaceted. For pet owners, the successful development and approval of OST-HER2 could offer a new therapeutic option for dogs diagnosed with osteosarcoma, potentially extending and improving their quality of life. For the veterinary community, it represents a shift towards more targeted, immunotherapy-based treatments, moving away from traditional chemotherapy and amputation. For investors, OS Therapies' dual focus on human and animal health (the parent company is also developing OST-HER2 for human cancers) provides a unique opportunity to invest in a platform technology with crossover applications.

OS Animal Health's efforts to re-establish USDA conditional approval are crucial. This regulatory pathway would allow the company to bring OST-HER2 to market more quickly, contingent on showing reasonable expectation of effectiveness. The company's strategy to become the “go-to” for HER2-positive cancers in dogs could create a strong competitive advantage, especially if it can secure first-mover status in the veterinary immunotherapy space.

The conference coverage, provided by IBN (InvestorBrandNetwork), is designed to increase visibility for participating companies. Through syndicated articles and social media, IBN is helping OS Animal Health reach a wider audience of potential investors and stakeholders. This exposure is vital for a company in the pre-revenue stage, as it seeks to fund clinical trials and regulatory processes. The coverage also underscores the legitimacy of the company's approach, as it is being highlighted among other disruptive growth companies in the life sciences sector.

For more information about OS Therapies and its veterinary oncology program, visit ostherapies.com. To register for the conference, visit Moody Capital Conference. To view IBN's coverage, visit IBN's Moody Capital Coverage.